CAR T-Cell Therapy Shows Promise in Marginal Zone Lymphoma | Lancet Study

A new clinical trial published in The Lancet offers a significant advancement in the treatment of relapsed or refractory marginal zone lymphoma (MZL), a rare type of non-Hodgkin lymphoma. Researchers found that CAR T-cell immunotherapy, specifically using lisocabtagene maraleucel (liso-cel), demonstrably improved both progression-free and overall survival rates for patients who have not responded to previous treatments. This is particularly encouraging for a patient population where effective options are limited and subsequent therapies often yield diminishing returns.

Understanding Marginal Zone Lymphoma

Marginal zone lymphoma is characterized by the abnormal growth of B-cells – a type of white blood cell – within lymphoid tissues. These tissues include lymph nodes, the stomach, and even bone marrow. Whereas often gradual-growing, MZL can become more aggressive, and relapse is a common challenge. Standard treatments include chemotherapy, immunotherapy, and targeted therapies, but these aren’t always successful long-term. For many, symptoms may not appear for years, meaning immediate treatment isn’t always necessary, but the potential for progression necessitates ongoing monitoring and research into more effective therapies.

The study, led by researchers who included Reem Karmali, MD, MS, associate professor of Medicine in the Division of Hematology and Oncology at Northwestern University’s Feinberg School of Medicine, enrolled 67 patients with MZL who had already undergone at least two prior lines of therapy. This highlights the focus on patients with limited treatment options. The findings represent a potential turning point for individuals facing this challenging diagnosis.

How CAR T-cell Therapy Works

CAR T-cell therapy is a form of immunotherapy that harnesses the power of the patient’s own immune system to fight cancer. The process involves collecting T-cells (another type of white blood cell) from the patient and genetically engineering them in a laboratory to express a chimeric antigen receptor (CAR). This CAR is designed to recognize a specific protein on the surface of lymphoma cells. Once re-infused into the patient, these re-engineered T-cells actively seek out and destroy cancer cells. In this trial, liso-cel was used, targeting a protein found on MZL cells. More details on the specifics of the liso-cel therapy can be found in the published abstract.

Trial Details and Limitations

The clinical trial involved patients enrolled at 30 sites across the United States. While the results are promising, it’s important to acknowledge the study’s limitations. The sample size of 67 patients is relatively small, and further research with larger cohorts is needed to confirm these findings and assess the long-term effects of liso-cel. The study focused on patients who had already received multiple prior treatments, which may limit the generalizability of the results to individuals with newly diagnosed MZL. The study does not establish whether liso-cel is superior to all other potential treatment options, only that it showed improvement in this specific patient group. Northwestern University News provides further context on the study’s findings.

The Significance for Patients and Clinicians

Dr. Karmali emphasized the historical challenges in treating MZL patients who have relapsed after multiple therapies. “Historically, patients with MZL who have had one to two treatments in the past struggle with maintaining a long-term response with subsequent therapies. We expect diminishing returns with each treatment,” she stated. This underscores the importance of finding new and effective treatment strategies for this population. The current study suggests that CAR T-cell therapy could offer a much-needed option for patients who have exhausted other avenues.

It’s crucial to understand that CAR T-cell therapy is not without potential side effects. These can include cytokine release syndrome (CRS) and neurotoxicity, which require careful monitoring and management by experienced healthcare professionals. However, the potential benefits in terms of improved survival may outweigh the risks for carefully selected patients.

Broader Context of CAR T-cell Therapy

CAR T-cell therapy has already demonstrated remarkable success in treating certain types of blood cancers, such as acute lymphoblastic leukemia. Its application to MZL represents an expansion of its potential benefits to a wider range of lymphoma subtypes. Research published in The Lancet in July 2024 likewise explored CD22-directed CAR T-cell therapy for large B-cell lymphomas, demonstrating the ongoing investigation into the versatility of this treatment approach. The development of CAR T-cell therapies is a rapidly evolving field, with ongoing research focused on improving efficacy, reducing side effects, and expanding its application to other cancers.

What Comes Next: Ongoing Research and Clinical Trials

The findings from this trial are expected to prompt further investigation into the use of liso-cel and other CAR T-cell therapies for MZL. Researchers will likely conduct larger, multi-center trials to confirm the results and identify biomarkers that can predict which patients are most likely to benefit from this treatment. Ongoing surveillance will also be crucial to monitor the long-term effects of CAR T-cell therapy and identify any potential late complications. Further studies are also needed to explore the optimal timing of CAR T-cell therapy within the treatment algorithm for MZL – whether it should be reserved for patients who have failed multiple prior lines of therapy or considered earlier in the course of the disease. Patients interested in learning more about clinical trials should consult with their healthcare provider and explore resources such as the National Cancer Institute’s clinical trials database.